Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Roche's Infectious Disease Portfolio To Include HCV Immunodiagnostics

By HospiMedica staff writers
Posted on 26 Nov 2007
Hepatitis C virus (HCV) infections frequently result in chronic liver disease. More...
They represent a major cause of death through the development of liver cirrhosis and liver cancer. HCV antibody tests are used for the primary diagnosis of HCV virus infection in patients with suspected liver disease. Positive anti-HCV results indicate the need for further investigation such as nucleic acid testing for viral RNA. Prognosis of HCV infection can be improved by anti-viral treatment, specifically interferon, and can be monitored using diagnostic tests.

Roche (Basel, Switzerland) announced licensing and settlement agreements with Ortho-Clinical Diagnostics, Inc. (Raritan, NJ, USA) and Novartis Vaccines & Diagnostics (Frimley/Camberley, UK) in the field of HCV diagnostics. Under the terms of the licensing agreement Ortho-Clinical Diagnostics, Inc. and Novartis Vaccines & Diagnostics granted Roche Diagnostics a worldwide royalty-bearing license under their broad patent portfolio for HCV in the field of immunodiagnostics. The agreement also includes cross licensing of patents owned by Roche Diagnostics. Financial terms of the deal were not disclosed.

The licensing agreement for HCV immunoassays will enable Roche Professional Diagnostics to expand its comprehensive product range in infectious diseases and to become a major player in this field, having already achieved a leading position in nucleic acid testing for hepatitis and retroviruses.

"We are pleased to have reached an agreement that provides Roche Diagnostics worldwide access to HCV immunoassays. This agreement will strengthen Roche's position in infectious disease diagnostics and will drive further growth of our immunoassay business worldwide,” commented Dirk Ehlers, head of Roche Professional Diagnostics.

Roche is a world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology, and active in other therapeutic areas such as autoimmune diseases, inflammation, metabolic disorders, and diseases of the central nervous system (CNS).


Related Links:
Roche
Ortho-Clinical Diagnostics
Novartis Vaccines & Diagnostics

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.